Search research articles
Contact Us
Filters
Showing results (111-120 of 130) with videos related to
Page
of 13
Sort By:
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
James Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
Nature Communications
|
August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Molecular Therapy. Methods & Clinical Development
|
June 14, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients
Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
The New England Journal of Medicine
|
October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
The New England Journal of Medicine
|
September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 130) with videos related to
Sort By:
Page
of 13
The New England Journal of Medicine
|
September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
James Larkin, Jeffrey Weber, Michele Del Vecchio, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
Nature Communications
|
August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Molecular Therapy. Methods & Clinical Development
|
June 14, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients
Tianjiao Wang, Jean-Marc Navenot, Stavros Rafail, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
The New England Journal of Medicine
|
October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
The New England Journal of Medicine
|
September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Page
of 13